OHSU

Seventy-eight percent of participants had at least one positive carrier screening result and 3.5 percent had a medically actionable secondary finding.

OHSU researchers will use Biological Dynamics' NanoVerita and ExoVerita lab-on-a-chip systems to develop early cancer detection methods.

OHSU was granted the rights to offer Biocept's Target Selector liquid biopsy testing services in Oregon as part of the deal. 

The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis.